ArticleJournal of gastrointestinal oncology2023

Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.

Jie Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.